{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:31:44Z","timestamp":1761845504274,"version":"3.41.2"},"reference-count":0,"publisher":"IMR Press","issue":"S1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Statins are first-line therapy for reducing atherosclerotic cardiovascular disease (ASCVD) risk. Some patients remain at high ASCVD risk despite maximizing statin therapy. Ezetimibe and proprotein convertase subtilisin\/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) have been shown to reduce ASCVD events in randomized trials and may be of benefit in selected high-risk patients with cardiovascular disease (CVD) or familial hypercholesterolemia (FH). Number-needed-to-treat (NNT) to prevent one ASCVD event can help identify groups of patients who may gain a net benefit from added nonstatin therapy. Patient groups with NNTs &lt;25 (in whom PCSK9 mAbs may approach cost effectiveness with discounting) include extremely high-risk patients (those with CVD with FH, polyvascular disease, or recurrent ASCVD events) with lowdensity lipoprotein cholesterol (LDL-C) levels \u226570 mg\/dL, very high-risk patients (those with CVD with diabetes [and no polyvascular disease], chronic kidney disease, or acute coronary syndromes, or CVD or FH with poorly controlled risk factors) with LDL-C levels \u2265100 mg\/dL, and high-risk patients (those with CVD or FH with well-controlled risk factors) with LDL-C \u2265130 mg\/dL. Ezetimibe, which is generic in the United States, is reasonable for patient groups with NNTs &lt;30, the level considered reasonable by most patients. This includes extremely high-risk patients with LDL-C levels \u2265130 mg\/dL, or very high-risk patients with LDL-C \u2265190 mg\/dL. All guidelines recommend statin therapy for the prevention of ASCVD.<\/jats:p>","DOI":"10.3909\/ricm19s1s0004","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T00:59:00Z","timestamp":1648429140000},"source":"Crossref","is-referenced-by-count":6,"title":["Identifying Patients for Nonstatin Therapy"],"prefix":"10.31083","volume":"19","author":[{"given":"Jennifer G.","family":"Robinson","sequence":"first","affiliation":[{"name":"Departments of Epidemiology & Medicine, University of Iowa College of Public Health and Carver College of Medicine, Iowa City, IA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karol E.","family":"Watson","sequence":"first","affiliation":[{"name":"Departments of Medicine & Cardiology, David Geffen School of Medicine at UCLA, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2018,1,20]]},"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/19\/S1\/10.3909\/ricm19S1S0004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T16:53:07Z","timestamp":1732726387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/19\/S1\/10.3909\/ricm19S1S0004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,20]]},"references-count":0,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2018]]}},"alternative-id":["1550738113333-712616908"],"URL":"https:\/\/doi.org\/10.3909\/ricm19s1s0004","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"type":"print","value":"1530-6550"},{"type":"electronic","value":"2153-8174"}],"subject":[],"published":{"date-parts":[[2018,1,20]]},"article-number":"1"}}